Literature DB >> 3150461

Emergence of imipenem-resistant Pseudomonas aeruginosa during treatment of intra-abdominal infection in a patient with ovarian carcinoma.

E H Sze, N G Osborne, M D Adelson, P Granato.   

Abstract

A 59-year-old woman was admitted to the hospital with ovarian carcinoma. After cytoreductive surgery, the patient developed intra-abdominal sepsis. After 17 days of intravenous imipenem, the patient's sputum culture grew imipenem-resistant Pseudomonas aeruginosa. On the 21st day of treatment with imipenem, her peritoneal culture also grew imipenem-resistant Pseudomonas aeruginosa.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3150461      PMCID： PMC2625865     

Source DB:  PubMed          Journal:  J Natl Med Assoc        ISSN： 0027-9684            Impact factor:   1.798


  17 in total

1.  Imipenem resistance in Pseudomonas aeruginosa is due to diminished expression of outer membrane proteins.

Authors:  K H Büscher; W Cullmann; W Dick; S Wendt; W Opferkuch
Journal:  J Infect Dis       Date:  1987-10       Impact factor: 5.226

2.  Empirical use of imipenem as the sole antibiotic in the treatment of serious infections.

Authors:  E H Freimer; H Donabedian; R Raeder; B S Ribner
Journal:  J Antimicrob Chemother       Date:  1985-10       Impact factor: 5.790

3.  Resistance of Pseudomonas aeruginosa mutants with altered control of chromosomal beta-lactamase to piperacillin, ceftazidime, and cefsulodin.

Authors:  L E Bryan; S Kwan; A J Godfrey
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

4.  Imipenem/cilastatin versus gentamicin/clindamycin for treatment of serious bacterial infections. Report from a Scandinavian Study Group.

Authors: 
Journal:  Lancet       Date:  1984-04-21       Impact factor: 79.321

5.  In vitro susceptibility of methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains to N-formimidoyl thienamycin.

Authors:  J L Witte; F L Sapico; H N Canawati
Journal:  Antimicrob Agents Chemother       Date:  1982-11       Impact factor: 5.191

6.  Mutation of Pseudomonas aeruginosa to piperacillin resistance mediated by beta-lactamase production.

Authors:  S M Bell; J N Pham; J Y Lanzarone
Journal:  J Antimicrob Chemother       Date:  1985-06       Impact factor: 5.790

7.  Imipenem therapy of Pseudomonas aeruginosa and other serious bacterial infections.

Authors:  D J Winston; M A McGrattan; R W Busuttil
Journal:  Antimicrob Agents Chemother       Date:  1984-11       Impact factor: 5.191

8.  Outer membrane permeability in Pseudomonas aeruginosa: comparison of a wild-type with an antibiotic-supersusceptible mutant.

Authors:  B L Angus; A M Carey; D A Caron; A M Kropinski; R E Hancock
Journal:  Antimicrob Agents Chemother       Date:  1982-02       Impact factor: 5.191

9.  Therapy for lower respiratory tract infections with imipenem/cilastatin: a review of worldwide experience.

Authors:  J F Acar
Journal:  Rev Infect Dis       Date:  1985 Jul-Aug

10.  Imipenem/cilastatin treatment of multiresistant Pseudomonas aeruginosa lung infection in cystic fibrosis.

Authors:  S S Pedersen; T Pressler; N Høiby; M W Bentzon; C Koch
Journal:  J Antimicrob Chemother       Date:  1985-11       Impact factor: 5.790
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.